

OCT 15 2004

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 28

## Complete If Known

Application Number	10/771,833
Filing Date	02/03/2004
First Named Inventor	Michael V. Milburn
Group Art Unit	
Examiner Name	

Attorney Docket Number 039363-1106

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
AK	A1	4,568,649		Bertoglio-Matte	02-04-1986	
	A2	4,626,513		Burton et al.	12-02-1986	
	A3	5,143,854		Pirrung et al.	09-01-1992	
	A4	5,426,039		Wallace et al.	06-20-1995	
	A5	5,434,049		Okano et al.	07-18-1995	
	A6	5,449,614		Danos et al.	09-12-1995	
	A7	5,474,935		Chatterjee et al.	12-12-1995	
	A8	5,556,752		Lockhart et al.	09-17-1996	
	A9	5,580,859		Feigner et al.	12-03-1996	
	A10	5,631,236		Woo et al.	05-20-1997	
	A1	5,632,957		Heller et al.	05-27-1997	
	A2	5,658,775		Gilboa	08-19-1997	
	A3	5,700,637		Southern	12-23-1997	
	A4	5,721,118		Scheffler	02-24-1998	
	A5	5,744,305		Fodor et al.	04-28-1998	
	A6	5,747,276		Hoch et al.	05-05-1998	
	A7	5,763,198		Hirth et al.	06-09-1998	
	A8	5,770,456		Holmes	06-23-1998	
	A9	5,800,992		Fodor et al.	09-01-1998	
	A10	5,807,522		Brown et al.	09-15-1998	
	A11	5,830,645		Pinkel et al.	11-03-1998	
	A12	5,856,174		Lipshutz et al.	01-05-1999	
	A13	5,877,007		Housey	03-02-1999	
	A14	5,959,098		Goldberg et al.	09-28-1999	
	A15	5,965,452		Kovacs	10-12-1999	
	A16	6,013,440		Lipshutz et al.	01-11-2000	
	A17	6,022,963		McGall et al.	02-08-2000	
	A18	6,025,155		Hadlaczky et al.	02-15-2000	
	A19	6,043,252		Bombrun	03-28-2000	
	A20	6,045,996		Cronin et al.	04-04-2000	
	A21	6,048,695		Bradley et al.	04-11-2000	
	A22	6,054,270		Southern	04-25-2000	
	A23	6,066,634		Sperl et al.	05-23-2000	
	A24	6,096,718		Weitzman et al.	08-01-2000	
	A25	6,107,478		Pedersen et al.	08-22-2000	
	A26	6,110,456		During	08-29-2000	
	A27	6,110,458		Freeman et al.	08-29-2000	
	A28	6,113,913		Brough et al.	09-05-2000	

Examiner Signature

*flynn*

Date Considered

6/12/2008

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/771,833
				Filing Date	02/03/2004
				First Named Inventor	Michael V. Milburn
				Group Art Unit	
				Examiner Name	
(use as many sheets as necessary)				Attorney Docket Number	039363-1106
Sheet	2	of	28		

U.S. PATENT DOCUMENTS					
<i>AK</i>	A29	6,117,681		Salmons et al.	09-12-2000
	A30	6,143,746		Daugan et al.	11-07-2000
	A31	6,143,757		Daugan et al.	11-07-2000
	A32	6,166,219		Yamasaki et al.	12-26-2000
	A33	6,178,384		Kolossvary	01-23-2001
	A34	6,243,980		Bronstein et al.	06-12-2001
	A35	6,258,606		Kovacs	07-10-2001
	A36	6,261,776		Pirrung et al.	07-17-2001
	A37	6,277,489		Abbott et al.	08-21-2001
	A38	6,277,628		Johann et al.	08-21-2001
	A39	6,294,330		Michnick et al.	09-25-2001
	A40	6,333,330		Bunnage et al.	12-25-2001
	A41	6,407,114		Bunnage et al.	06-18-2002
	A42	6,440,982		Maw et al.	08-27-2002
	A43	6,451,807		Emmick et al.	09-17-2002
	A44	6,492,371		Roylance	12-10-2002
	A45	6,500,610		Pamuukeu et al.	12-31-2002
	A46	6,503,908		Maw	01-07-2003

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)			
<i>AK</i>	A47	EP	0463756	A	Pfizer Inc.	04-19-1995	
	A48	EP	0526004	A	Pfizer Limited and Pfizer Inc.	10-08-1997	
	A49	EP	0995751	A	Pfizer Limited and Pfizer Inc.	04-26-2000	
	A50	EP	0995750	A	Pfizer Limited and Pfizer Inc.	04-26-2000	
	A51	EP	0,154,734		Immunex Corporation	08-29-1990	
	A52	WO	00/24745		Pfizer Limited and Pfizer Inc.	05-04-2000	
	A53	WO	03/038080		Pfizer Limited	05-08-2003	
	A54	WO	93/06104		Pfizer Limited and Pfizer Inc.	04-01-1993	
	A55	WO	93/07124		Eisai Co.	04-15-1993	
	A56	WO	93/07149		Pfizer Limited and Pfizer Inc.	04-15-1993	

Examiner Signature	<i>Shubh</i>	Date Considered	6/12/06
--------------------	--------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.


Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/771,833
				Filing Date	02/03/2004
				First Named Inventor	Michael V. Milburn
				Group Art Unit	
				Examiner Name	
(use as many sheets as necessary)				Attorney Docket Number	
Sheet	3	of	28	039363-1106	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
AK	A57	WO	93/12095		Pfizer Limited and Pfizer Inc.	06-24-1993		
	A58	WO	94/00453		Pfizer Limited and Pfizer Inc.	01-06-1994		
	A59	WO	95/19978		Laboratories Glaxco S.A.	07-27-1995		
	A60	WO	96/17958		The Regents of the University of California and The medical Research Council	06-13-1996		
	A61	WO	96/18738		Sugen Inc. and New York university	06-20-1996		
	A62	WO	97/46313		Array Technologies	12-11-1997		
	A63	WO	98/49166		Pfizer Limited	11-05-1998		
	A64	WO	99/09217		Hyseq, Inc.	02-25-1999		
	A65	WO	99/51773		Phylos, Inc.	10-14-1999		
N	A66	WO	99/54333		Pfizer Inc. and Pfizer Limited	10-28-1999		

NON PATENT LITERATURE DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.					T <sup>6</sup>	
AK	A67	AARONSON, "Growth Factors and Cancer," <i>Science</i> 254:1146-1153 (1991)						
	A68	ALFTHAN, "Surface Plasmon Resonance Biosensors as a Tool in Antibody Engineering," <i>Biosensors &amp; Bioelectronics</i> 13:653-663 (1998)						
	A69	AL-OBEIDI, "Peptide and Peptidomimetic Libraries – Molecular Diversity and Drug Design," <i>Mol Biotechnol</i> 9(3):205-223 (1998)						
	A70	AMERSDORFER and MARKS, "Phage Libraries for Generation of Anti-Botulinum scFv Antibodies," <i>Methods in Molecular Biology</i> 145:219-240 (2001)						
↓	A71	BAGSHAW and HARRIS, "Measurement of Ligand Binding to Proteins," <i>Spectrophotometry and Spectrofluorometry: A Practical Approach</i> 4:91-114 (1987)						

Examiner Signature		Date Considered	6/15/06
--------------------	---	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/771,833
				Filing Date	02/03/2004
				First Named Inventor	Michael V. Milburn
				Group Art Unit	
				Examiner Name	
(use as many sheets as necessary)				Attorney Docket Number	
Sheet	4	of	28	039363-1106	

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>6</sup>
AK	A72	BAKRE <i>et al.</i> , <i>FEBS Lett.</i> , 408:345-349 (1997)		
	A73	BALLARD <i>et al.</i> , <i>J. Urol.</i> , 159:2164-2171 (1998)		
	A74	BARTLETT <i>et al.</i> , "CAVEAT: A Program to facilitate the structure-derived design of biologically active molecules." In <i>Molecular Recognition: Chemical and Biological Problems</i> . The Proceedings of an International Symposium, University of Exeter, April 1989, <i>Royal Society of Chemistry</i> , Cambridge 182-196 (1989)		
	A75	BEAVO, <i>et al.</i> , "Multiple Cyclic Nucleotide Phosphodiesterases," <i>Mol. Pharmacol.</i> 46:399-405 (1994)		
	A76	BELL, "Spectroscopy In Biochemistry," <i>CRC Press</i> I:155-194 (1981)		
	A77	BELLIS <i>et al.</i> , "Characterization of Tyrosine Phosphorylation of Paxillin in Vitro by Focal Adhesion Kinase," <i>J. Biol. Chem.</i> 270:17437-17441 (1995)		
	A78	BERTHET, <i>et al.</i> , "The Assay of Glucagon and Epinephrine with Use of Liver Homogenates," <i>J. Biol. Chem.</i> 229:351-361 (1957)		
	A79	BLUNDELL <i>et al.</i> , "Knowledge-Based Protein Modeling and Design," <i>Eur. J. Biochem.</i> 172:513 (1988)		
	A80	BÖHM, "On the Use of LUDI to Search the Fine Chemicals Directory for Ligands of Proteins of Known Three-Dimensional Structure," <i>J. Comp. Aided Molec. Design</i> 8:623 (1994)		
↓	A81	BOLGER and SHERMAN, "Computer Modeling of Combing Site Structure of Anti-Hapten Monoclonal Antibodies," <i>Methods Enz.</i> 203:21-45 (1991)		

Examiner Signature		Date Considered	6/15/06
--------------------	---	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/771,833
				Filing Date	02/03/2004
				First Named Inventor	Michael V. Milburn
				Group Art Unit	
				Examiner Name	
(use as many sheets as necessary)				Attorney Docket Number	039363-1106
Sheet	5	of	28		

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>6</sup>
AK	A82	BOWTELL, "Options Available – From Start to Finish – For Obtaining Expression Data by Microarray," <i>Nature Genetics Supp.</i> 21:25-32 (1999)			
	A83	BRENNER <i>et al.</i> , "Encoded Combinatorial Chemistry," <i>Proc. Natl. Acad. Sci. USA</i> , 89:5381-5383 (1992)			
	A84	BROWN and BIRNBAUMER, "Ionic Channels and Their Regulation by G Protein Subunits," <i>Ann. Rev. Physiol.</i> 52:197-213 (1990)			
	A85	BRÜNGER, "Free R Value: A Novel Statistical Quantity for Assessing the Accuracy of Crystal Structures," <i>Nature</i> 355:472-475 (1992)			
	A86	BUCHSCHER and PANGANIBAN, "Human Immunodeficiency Virus Vectors for Inducible Expression of Foreign Genes," <i>J. Virol.</i> 66:2731-2739 (1992)			
	A87	BURNS <i>et al.</i> , "The Catalytic Subunit of Protein Kinase A Triggers Activation of the Type V Cyclic GMP-Specific Phosphodiesterase from Guinea-Pig Lung," <i>Biochem. J.</i> , 283:487-491 (1992)			
	A88	CAPON <i>et al.</i> , "Designing CD4 Immunoadhesions for AIDS Therapy," <i>Nature</i> 377:525-531 (1989)			
✓	A89	CARELL <i>et al.</i> , "New Promise in Combinatorial Chemistry: Synthesis, Characterization, and Screening of Small-Molecule Libraries Solution," <i>Chem. Biol.</i> 3:171-183 (1995)			

Examiner Signature		Date Considered	6/15/06
--------------------	---	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<b>Complete If Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	10/771,833
				Filing Date	02/03/2004
				First Named Inventor	Michael V. Milburn
				Group Art Unit	
				Examiner Name	
(use as many sheets as necessary)				Attorney Docket Number	
Sheet	6	of	28	039363-1106	

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			
AK	A90	CHABALA, "Solid-Phase Combinatorial Chemistry and Novel Tagging Methods for Identifying Leads," <i>Curr Opin Biotechnol</i> 6(6):633-639 (1995)			
	A91	CHARBONNEAU, H., "Structure-Function Relationships Among Cyclic Nucleotide Phosphodiesterases," <i>Cyclic Nucleotide Phosphodiesterases: Structure, Regulation and Drug Action</i> , pp. 267-296 (1990)			
	A92	CHECOVICH, et al., "Fluorescence Polarization – A New Tool for Cell and Molecular Biology," <i>Nature</i> 375:254-256 (1995)			
	A93	CLARK et al., "PRO-LIGAND: An Approach to De Novo Molecular Design. 1. Application to the Design of Organic Molecules," <i>J. Comp. Aided Molec. Design</i> 9:13-32 (1995)			
	A94	COBB et al., "Stable Association of pp60 <sup>src</sup> and pp59 <sup>yn</sup> with the Focal Adhesion-Associated Protein Tyrosine Kinase, pp125 <sup>FAK</sup> ," <i>Mol. Cell. Biol.</i> 14(1):147-155 (1994)			
	A95	COE et al., "Solution-Phase Combinatorial Chemistry," <i>Mol Divers.</i> 4(1):31-38 (1998-99)			
	A96	COLLIUOD et al., "Oriented and Covalent Immobilization of Target Molecules to Solid Supports: Synthesis and Application of a Light-Activatable and Thiol-Reactive Cross-Linking Reagent," <i>Bioconjugate Chem.</i> 4:528-536 (1993)			
↓	A97	COLMAN, "Structure-Based Design," <i>Current Opinion in Struc. Biol.</i> 4:868 (1994)			

Examiner Signature		Date Considered	6/15/06
--------------------	---	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/771,833
				Filing Date	02/03/2004
				First Named Inventor	Michael V. Milburn
				Group Art Unit	
				Examiner Name	
(use as many sheets as necessary)				Attorney Docket Number	039363-1106
Sheet	7	of	28		

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.				T <sup>6</sup>
<i>AK</i>	A98	CONTI <i>et al.</i> , "Recent Progress in Understanding the Hormonal Regulation of Phosphodiesterases," <i>Endocr. Rev.</i> , 16:370-389 (1995)				
<i>AK</i>	A99	CORBIN and FRANCIS, "Cyclic GMP Phosphodiesterase-5: Target of Sildenafil," <i>The Journal of Biological Chemistry</i> 274(20):13729-13732 (1999)				
	A100	CREIGHTON, "An Empirical Approach to Protein Conformation Stability and Flexibility," <i>Biopolymers</i> 22(1):49-58 (1983)				
	A101	CWIRLA <i>et al.</i> , "Peptides on Phage: A Vast Library of Peptides for Identifying Ligands," <i>Biochemistry</i> 87:6378-6382 (1990)				
	A102	DANDLIKER, <i>et al.</i> , "Equilibrium and Kinetic Inhibition Assays Based Upon Fluorescence Polarization," <i>Methods in Enzymology</i> 74:3-28 (1981)				
	A103	DAVIS <i>et al.</i> , "Purification and Characterization of Guanosine 3':5' - Monophosphate-Specific Phosphodiesterase from Guinea Pig Lung," <i>J. Biol. Chem.</i> 252:4078-4084 (1977)				
	A104	DEGERMAN <i>et al.</i> , "Structure, Localization, and Regulation of cGMP-inhibited Phosphodiesterase (PDE3)," <i>J. Biol. Chem.</i> 272:6823-6826 (1997)				
<i>✓</i>	A105	DIKIC <i>et al.</i> , "A Role For Pyk2 and Src in Linking G-Protein-Coupled Receptors with MAP Kinase Activation," <i>Nature</i> 383:547-550 (1996)				

Examiner Signature	<i>Michael V. Milburn</i>	Date Considered	6/18/06
--------------------	---------------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Application Number	10/771,833	
			Filing Date	02/03/2004	
			First Named Inventor	Michael V. Milburn	
			Group Art Unit		
			Examiner Name		
(use as many sheets as necessary)					
Sheet	8	of	28	Attorney Docket Number	039363-1106

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>6</sup>
AK	A106	DOBELI, "Recombinant Fusion Proteins for the Industrial Production of Disulfide Bridge Containing Peptides: Purification, Oxidation Without Concatamer Formation, and Selective Cleavage," <i>Protein Expr. Purif.</i> 12:404-414 (1998)			
	A107	DOLLE and NELSON, "Comprehensive Survey of Combinatorial Library Synthesis: 1998," <i>J Comb Chem</i> 1(4):235-282 (1999)			
	A108	DOLPHIN, "G Protein Modulation of Calcium Currents in Neurons," <i>Ann. Rev. Physiol.</i> 52:243-255 (1990)			
	A109	DUONG <i>et al.</i> , "PYK2 in Osteoclasts is an Adhesion Kinase, Localized in the Sealing Zone, Activated by Ligation of $\alpha_1\beta_3$ Integrin, and Phosphorylated by Src Kinase," <i>J Clin Invest.</i> 102:881-892 (1998)			
	A110	ELISEEV and LEHN, "Dynamic Combinatorial Chemistry: Evolutionary Formation and Screening of Molecular Libraries," <i>Current Topics in Microbiology &amp; Immunology</i> 243:159-172 (2000)			
	A111	ENJALBAL <i>et al.</i> , "Mass Spectrometry in Combinatorial Chemistry," <i>Mass Spectrometry Reviews</i> , 19:139-161 (2000)			
	A112	FENG, <i>et al.</i> , "Stable <i>in Vivo</i> Transduction Via a Novel Adenoviral/Retroviral Chimeric Vector," <i>Nature Biotechnology</i> 15:866-870 (1997)			
✓	A113	FISCHER and SCHONBRUNN, "The Bombesin Receptor is Coupled to a Guanine Nucleotide-Binding Protein Which is Insensitive to Pertussis and Cholera Toxins," <i>J. Biol. Chem.</i> 263(6):2808-2816 (1988)			

Examiner Signature		Date Considered	6/15/06
--------------------	---	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/771,833
				Filing Date	02/03/2004
				First Named Inventor	Michael V. Milburn
				Group Art Unit	
				Examiner Name	
(use as many sheets as necessary)				Attorney Docket Number	039363-1106
Sheet	9	of	28		

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.				T <sup>6</sup>
AK	A114	FIVASH et al., "BIAcore for Macromolecular Interaction," <i>Current Opinion in Biotechnology</i> 9:97-101 (1998)				
	A115	FLORIO et al., "Phosphorylation of the 61-kDa Calmodulin-Stimulated Cyclic Nucleotide Phosphodiesterase at Serine 120 Reduces Its Affinity for Calmodulin," <i>Biochemistry</i> 33:8948-8954 (1994)				
	A116	FRANCIS et al., "Cyclic GMP-Binding Cyclic GMP-Specific Phosphodiesterase From Lung," <i>Cyclic Nucleotide Phosphodiesterases: Structure, Regulation and Drug Action</i> , Beavo, J., and Houslay, M.D., eds, 117-140, John Wiley & Sons, Inc., New York (1990)				
	A117	FRANCIS et al., "Characterization of a Novel cGMP Binding Protein from Rat Lung," <i>J. Biol. Chem.</i> 255:620-626 (1980)				
	A118	FRANCIS et al., "Zinc Interactions and Conserved Motifs of the cGMP-binding cGMP-specific Phosphodiesterase Suggest That It Is a Zinc Hydrolase," <i>J. Biol. Chem.</i> 269:22477-22480 (1994)				
	A119	FRANCIS et al., "Purification of cGMP-Binding Protein Phosphodiesterase from Rat Lung," <i>Methods Enzymol.</i> 159:722-729 (1988)				
	A120	FRANCIS et al., "Ligand-Induced Conformational Changes in Cyclic Nucleotide Phosphodiesterases and Cyclic Nucleotide-Dependant Protein Kinases," <i>Methods</i> 14:81-92 (1998)				
✓	A121	FREIDINGER, RM., "Nonpeptidic Ligands for Peptide and Protein Receptors," <i>Current Opinion in Chemical Biology</i> 3:395-406 (1999)				

Examiner Signature		Date Considered	6/15/06
--------------------	---	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/771,833
				Filing Date	02/03/2004
				First Named Inventor	Michael V. Milburn
				Group Art Unit	
				Examiner Name	
(use as many sheets as necessary)					
Sheet	10	of	28	Attorney Docket Number	039363-1106

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
AK	A122	FRUCHT, et al., "Characterization of Functional Receptors for Gastrointestinal Hormones on Human Colon Cancer Cells," <i>Cancer Research</i> 52:1114-1122 (1992)	
	A123	FURCHGOTT and VANHOUTTE, "Endothelium-Derived Relaxing and Contracting Factors," <i>FASEB J.</i> 3:2007-2018 (1997)	
	A124	GALLOP et al., "Applications of Combinatorial Technologies to Drug Discovery. 1. Background and Peptide Combinatorial Libraries," <i>J. Med. Chem.</i> 37:1233-1251 (1994)	
	A125	GETTYS, et al., "Short-term Feedback Regulation of cAMP by Accelerated Degradation in Rat Tissues," <i>J. Biol. Chem.</i> 262:333-339 (1987)	
	A126	GILMAN, A., "G Proteins: Transducers of Receptor-Generated Signals," <i>Ann. Rev. Biochem.</i> 56:615-649 (1987)	
	A127	GOODFORD, P., "A Computational Procedure for Determining Energetically Favorable Binding Sites on Biologically Important Macromolecules," <i>J. Med. Chem.</i> 28:849-857 (1985)	
	A128	GOODSELL and OLSON, "Automated Docking of Substrates to Proteins by Simulated Annealing," <i>Proteins: Structure, Function, and Genetics</i> 8:195-202 (1990)	
✓	A129	GORDON et al., "Applications of Combinatorial Technologies to Drug Discovery. 2. Combinatorial Organic Synthesis, Library Screening Strategies, and Future Directions," <i>J. Med. Chem.</i> 37:1385-1401 (1994)	

Examiner Signature		Date Considered	6/15/06
--------------------	---	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/771,833
				Filing Date	02/03/2004
				First Named Inventor	Michael V. Milburn
				Group Art Unit	
				Examiner Name	
(use as many sheets as necessary)				Attorney Docket Number	
Sheet 11		of 28			039363-1106

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
AK	A130	GORDON and FORD, "Detection of Peroxides and Their Removal," <i>The Chemist's Companion: A Handbook of Practical Data, Techniques, and References</i> , p. 437 (1972)	
	A131	GRAM H., "Phage Display in Proteolysis and Signal Transduction," <i>Combinatorial Chemistry &amp; High Throughput Screening</i> 2:19-28 (1999)	
	A132	GRAVERT and JANDA, "Synthesis on Soluble Polymers: New Reactions and the Construction of Small Molecules," <i>Curr Opin Chem Biol</i> 1(1):107-113 (1997)	
	A133	GREER, J., "Model Structure for the Inflammatory Protein C5a," <i>Science</i> 228:1055-1060 (1985)	
	A134	GRESSER and GLEITER, "Erectile Dysfunction Comparison of Efficacy and Side Effects of the PDE-5 Inhibitors Sildenafil, Vardenafil and Tadalafil Review of the Literature," <i>Eur J Med Res</i> 7:435-446 (2002)	
	A135	GUIDA, C., "Software for Structure-Based Drug Design," <i>Current Opinion in Struc. Biol.</i> 4:777-781 (1994)	
	A136	GUMBINER, B., "Proteins Associated with the Cytoplasmic Surface of Adhesion Molecules," <i>Neuron</i> , 11:551-564 (1993)	
↓	A137	HAFNER et al., "Isothermal Amplification and Multimerization of DNA by Bst DNA Polymerase," <i>Biotechniques</i> 30:852-867 (2001)	

Examiner Signature		Date Considered	8/15/06
--------------------	---	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Application Number	10/771,833	
			Filing Date	02/03/2004	
			First Named Inventor	Michael V. Milburn	
			Group Art Unit		
			Examiner Name		
(use as many sheets as necessary)					
Sheet	12	of	28	Attorney Docket Number	039363-1106

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
AK	A138	HAMET et al., "Cyclic GMP Binding and Cyclic GMP Phosphodiesterase in Rat Platelets," <i>J. Cyclic Nucleotide Res.</i> 4:281-290 (1978)	
~	A139	HANSELMAN et al., "A cDNA-Dependant Scintillation Proximity Assay for Quantifying Apolipoprotein A-1," <i>J. Lipid Res.</i> 38:2365-2373 (1997)	
	A140	HARTMANN, H. "Moleküldesign Bei Fluoreszenzfarbstoffen," <i>Chimia</i> 48:512-514 (1994)	
	A141	HAUCK et al., "Focal Adhesion Kinase Functions as a Receptor-Proximal Signaling Component Required for Directed Cell Migration," <i>Immunol Res.</i> 21:293-303 (2000)	
	A142	HEIM and TSIEN, "Engineering Green Fluorescent Protein for Improved Brightness, Longer Wavelengths and Fluorescence Resonance Energy Transfer," <i>Curr. Biol.</i> 6:178-182 (1996)	
	A143	HILDEBRAND, et al., "Identification of Sequences Required for the Efficient Localization of the Focal Adhesion Kinase, p1125 <sup>FAK</sup> , to Cellular Focal Adhesions," <i>J. Cell Biol.</i> 123(4):993-1005 (1993)	
	A144	HILDEBRAND, et al., "An SH3 Domain-Containing GTPase-Activating Protein for Rho and Cdc42 Associates with Focal Adhesion Kinase," <i>Mol Cell Biol.</i> 16:3169-3178 (1996)	
~	A145	HILLE, B., "G Protein-Coupled Mechanisms and Nervous Signaling," <i>Neuron</i> 9:187-195 (1992)	

Examiner Signature		Date Considered	6/15/06
--------------------	---	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/771,833
				Filing Date	02/03/2004
				First Named Inventor	Michael V. Milburn
				Group Art Unit	
				Examiner Name	
(use as many sheets as necessary)				Attorney Docket Number	039363-1106
Sheet	13	of	28		

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
JK	A146	HOUGHTEN <i>et al.</i> , "Generation and Use of Synthetic Peptide Combinatorial Libraries for Basic Research and Drug Discovery," <i>Nature</i> 354:84-86 (1991)	
	A147	HOUGHTEN, "Peptide Libraries: Criteria and Trends," <i>Trends in Genetics</i> 9(7):235-239 (1993)	
	A148	HOUGHTEN, "Parallel Array and Mixture-Based Synthetic Combinatorial Chemistry: Tools for the Next Millenium," <i>Annu Rev Pharmacol Toxicol</i> 40:273-282 (2000)	
	A149	HOUSLAY, M.D., "Compartmentalization of Cyclic AMP Phosphodiesterases, Signaling 'Crosstalk', Desensitization and the Phosphorylation of G <sub>i</sub> -2 Add Cell Specific Personalization to the Control of the Levels of the Second Messenger Cyclic AMP," <i>Adv. Enzyme Regul.</i> 35:303-338 (1995)	
	A150	HUANG, <i>et al.</i> , "Tyrosine Kinase-Dependant Suppression of a Potassium Channel by the G Protein-Coupled m1 Muscarinic Acetylcholine Receptor," <i>Cell</i> 75:1145-1156 (1993)	
	A151	HUGHES-JONES <i>et al.</i> , "Synthesis of Rh Fv Phage-Antibodies Using VH and VL Germline Genes," <i>British Journal of Haematology</i> 105:811-816 (1999); McCall AM. Amoroso AR. Sautes C. Marks JD. Weiner LM., Characterization of anti-mouse Fc gamma RII single-chain Fv fragments derived from human phage display libraries, <i>Immunotechnology</i> . 4:71-87, (1998)	
	A152	HYNES, R., "Integrins: Bidirectional, Allosteric Signaling Machines," <i>Cell</i> 110:673-687 (2002)	
↓	A153	IWANE <i>et al.</i> , "Myosin Subfragment-1 is Fully Equipped with Factors Essential for Motor Function," <i>Biophys. Biochem. Res. Comm.</i> 230:76-80 (1997)	

Examiner Signature		Date Considered	6/15/06
--------------------	---	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/771,833
				Filing Date	02/03/2004
				First Named Inventor	Michael V. Milburn
				Group Art Unit	
				Examiner Name	
(use as many sheets as necessary)				Attorney Docket Number	039363-1106
Sheet	14	of	28		

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>6</sup>
AK	A154	JOHANN, et al., "GLVR1, a Receptor for Gibbon Ape Leukemia Virus, is Homologous to a Phosphate Permease of Neurospora Crassa and is Expressed at High Levels in the Brain and Thymus," <i>J. Virol.</i> 66:1635-1640 (1992)			
	A155	JOHNSTON, M., "Gene Chips: Array of Hope for Understanding Gene Regulation," <i>Curr. Biol.</i> 8:R171-R174 (1998)			
	A156	JONES, T., "Interactive Computer Graphics," <i>Methods in Enzymology</i> 115:157-171 (1985)			
	A157	JOSEPH-MCCARTHY D., "Computational Approaches to Structure-Based Ligand Design," <i>Pharmacology &amp; Therapeutics</i> 84:179-191 (1999)			
	A158	KAHL et al., "A Multiple-Approach Scintillation Proximity Assay to Measure the Association Between Ras and Raf," <i>Anal. Biochem.</i> 243:282-283 (1996)			
	A159	KERN and HAMPTON, "Direct Hybridization of Large-Insert Genomic Clones on High-Density Gridded cDNA Filter Arrays," <i>Biotechniques</i> 23:120-124 (1997)			
	A160	KIM and KAHN, "A Merger of Rational Drug Design and Combinatorial Chemistry: Development and Application of Peptide Secondary Structure Mimetics," <i>Combinatorial Chemistry &amp; High Throughput Screening</i> 3:167-183 (2000)			
↓	A161	KIRKPATRICK et al., "Structure-Based Drug Design: Combinatorial Chemistry and Molecular Modeling," <i>Combinatorial Chemistry &amp; High Throughput Screening</i> 2:211-221 (1999)			

Examiner Signature		Date Considered	8/15/06
--------------------	---	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/771,833
				Filing Date	02/03/2004
				First Named Inventor	Michael V. Milburn
				Group Art Unit	
				Examiner Name	
(use as many sheets as necessary)				Attorney Docket Number	039363-1106
Sheet	15	of	28		

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>6</sup>
AK	A162	KLINE et al., "Studies by <sup>1</sup> H Nuclear Magnetic Resonance and Distance Geometry of the Solution Conformation of the x-Amylase Inhibitor Tendamistat," <i>J. Mol. Biol.</i> 189:377-382 (1986)			
	A163	KNIGHTON et al., "Structural Basis of the Intrasteric Regulation of Myosin Light Chain Kinases," <i>Science</i> 258:130-135 (1992)			
	A164	KOLASKAR and TONGAONKAR, "A Semi-Empirical Method for Prediction of Antigenic Determinants on Protein Antigens," <i>FEBBS Lett.</i> 276(1-2):172-174 (1990)			
	A165	KOTERA, et al., "Expression of Rat cGMP-Binding cGMP-specific Phosphodiesterase mRNA in Purkinje Cell Layers During Postnatal Neuronal Development," <i>Eur. J. Biochem.</i> 249(2):434-442 (1997)			
	A166	KROLL, et al., "A Multifunctional Prokaryotic Protein Expression System: Overproduction, Affinity Purification, and Selective Detection," <i>DNA Cell. Biol.</i> 12:441-453 (1993)			
	A167	KUNDU et al., "Combinatorial Chemistry: Polymer Supported Synthesis of Peptide and Non-Peptide Libraries," <i>Progress in Drug Research</i> 53:89-156 (1999)			
	A168	KUNKEL, T., "Rapid and Efficient Site-Specific Mutagenesis Without Phenotypic Selection," <i>Proc. Natl. Acad. Sci.</i> 82:488-492 (1985)			
↓	A169	KUNTZ et al., "Structure-Based Molecular Design," <i>Acc. Chem. Res.</i> 27:117-123 (1994)			

Examiner Signature		Date Considered	6/15/06
--------------------	---	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/771,833
				Filing Date	02/03/2004
				First Named Inventor	Michael V. Milburn
				Group Art Unit	
				Examiner Name	
(use as many sheets as necessary)				Attorney Docket Number	039363-1106
Sheet	16	of	28		

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>6</sup>
AK	A170	KUNTZ <i>et al.</i> , "A Geometric Approach to Macromolecule-Ligand Interactions," <i>J. Mol. Biol.</i> 161:269-288 (1982)			
	A171	LAKKAKORPI, <i>et al.</i> , "Stable Association of PYK2 and p130 <sup>cas</sup> in Osteoclasts and Their Co-Localization in the Sealing Zone," <i>J Biol Chem.</i> 274:4900-4907 (1999)			
	A172	LAM <i>et al.</i> , "A New Type of Synthetic Peptide Library for Identifying Ligand-Binding Activity," <i>Nature</i> 354:82-84 (1991)			
	A173	LEBL <i>et al.</i> , "One-Bead-One-Structure Combinational Libraries," <i>Biopolymers</i> 37:177-198 (1995)			
	A174	LEV, <i>et al.</i> , "Protein Tyrosine Kinase PYK2 Involved in Ca <sup>2+</sup> -Induced Regulation of Ion Channel and MAP Kinase Functions," <i>Nature</i> 376:737-745 (1995)			
	A175	LI and EARP, "Paxillin is Tyrosine-Phosphorylated by and Preferentially Associates With the Calcium-Dependent Tyrosine Kinase in Rat Liver Epithelial Cells," <i>J Biol Chem.</i> 272:14341-14348 (1997)			
	A176	LINCOLN, <i>et al.</i> , "Guanosine 3\$'-(prime)\$-Cyclic Monophosphate Binding Proteins in Rat Tissues," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 73:2559-2563 (1976); Yamazaki, <i>et al.</i> , <i>J. Biol. Chem.</i> 255:11619-11624 (1980)			
✓	A177	LIPAROTO and CIARDELLI, "Biosensor Analysis of the Interleukin-2 Receptor Complex," <i>Journal of Molecular Recognition</i> 12:316-321 (1999)			

Examiner Signature		Date Considered	6/15/06
--------------------	---	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/771,833
				Filing Date	02/03/2004
				First Named Inventor	Michael V. Milburn
				Group Art Unit	
				Examiner Name	
(use as many sheets as necessary)				Attorney Docket Number	039363-1106
Sheet	17	of	28		

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			
AK	A178	LIPINSKI <i>et al.</i> , "Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings," <i>Advanced Drug Delivery Reviews</i> 23:3-25 (1997)			
	A179	LIPSCHULTZ <i>et al.</i> , "Experimental Design for Analysis of Complex Kinetics Using Surface Plasmon Resonance," <i>Methods</i> 20(3):310-318 (2000)			
	A180	LOCHHEAD, <i>et al.</i> , "The Regulation of the cGMP -binding cGMP Phosphodiesterase by Proteins That Are Immunologically Related to $\gamma$ Subunit of the Photoreceptor cGMP Phosphodiesterase," <i>J. Biol. Chem.</i> 272(29):18397-18403 (1997)			
	A181	LOUGHNEY, <i>et al.</i> , "Isolation and Characterization of cDNAs Encoding PDE5A, a Human cGMP-Binding, cGMP-specific 3', 5'-Cyclic Nucleotide Phosphodiesterase," <i>Gene (Amst.)</i> 216:137-147 (1998)			
	A182	LU, <i>et al.</i> , Oriented Immobilization of Fab' Fragments on Silica Surfaces," <i>Anal. Chem.</i> 67:83-87 (1995)			
	A183	MADDEN <i>et al.</i> , "Synthetic Combinatorial Libraries: Views on Techniques and Their Application," <i>Perspectives in Drug Discovery and Design</i> 2:269-282 (1994)			
	A184	MALMBORG and BORREBAECK, "BIAcore as a Tool in Antibody Engineering, <i>Journal of Immunological Methods</i> 183:7-13 (1995)			
↓	A185	MALMQVIST <i>et al.</i> , "Biomolecular Interaction Analysis: Affinity Biosensor Technologies for Functional Analysis of Proteins," <i>Current Opinion in Chemical Biology</i> 1:378-383 (1997)			

Examiner Signature		Date Considered	6/15/08
--------------------	---	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	10/771,833
				Filing Date	02/03/2004
				First Named Inventor	Michael V. Milburn
				Group Art Unit	
				Examiner Name	
(use as many sheets as necessary)					
Sheet	18	of	28	Attorney Docket Number	039363-1106

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>6</sup>
<i>AM</i>	A186	MALMQVIST, M., "BIACORE: An Affinity Biosensor System For Characterization of Biomolecular Interactions," <i>Biochemical Society Transactions</i> 27:335-340 (1999)			
	A187	MARKIEWICZ et al., "Synthetic Oligonucleotide Combinatorial Libraries and Their Applications," <i>Farmaco</i> 55:174-177 (2000)			
	A188	MARTIN, Y., "Computer-Assisted Rational Drug Design," <i>Methods Enz.</i> 203:587-613 (1991)			
	A189	MARTINEZ et al., "The Two GAF Domains in Phosphodiesterase 2A Have Distinct Roles in Dimerization and in cGMP Binding," <i>Proc Natl Acad Sci USA</i> 99:13260-13265 (2002)			
	A190	McALLISTER-LUCAS, et al., "The Structure of a Bovine Lung cGMP-binding, cGMP-specific Phosphodiesterase Deduced from a cDNA Clone," <i>J. Biol. Chem.</i> 268:22863-22873 (1993)			
	A191	McALLISTER-LUCAS et al., "An Essential Aspartic Acid at Each of Two Allosteric cGMP-binding Sites of a cGMP-specific Phosphodiesterase," <i>J. Biol. Chem.</i> 270:30671-30679 (1995)			
	A192	MCCALL, et al., "Characterization of Anti-Mouse Fcγ RII Single-Chain Fv Fragments Derived from Human Phage Display Libraries," <i>Immunotechnology</i> 4:71-87 (1998)			
<i>✓</i>	A193	McPHERSON, A., "Current Approaches to Macromolecular Crystallization," <i>Eur. J. Biochem.</i> 189:1-23 (1990)			

Examiner Signature	<i>Clayell</i>	Date Considered	6/15/06
--------------------	----------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<b>Complete If Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	10/771,833
				Filing Date	02/03/2004
				First Named Inventor	Michael V. Milburn
				Group Art Unit	
				Examiner Name	
(use as many sheets as necessary)				Attorney Docket Number	039363-1106
Sheet	19	of	28		

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>8</sup>
AK	A194	MCSHAN <i>et al.</i> , "Csk Homologous Kinase Associates with RAFTK/Pyk2 in Breast Cancer Cells and Negatively Regulates its Activation and Breast Cancer Cell Migration," <i>Internat. J. Oncology</i> 21:197-205 (2002)	
	A195	MENG <i>et al.</i> , "Automated Docking With Grid-Based Energy Evaluation," <i>J. Compt. Chem.</i> 13:505:524 (1992)	
	A196	MERRITT, A., "Solution Phase Combinatorial Chemistry," <i>Comb Chem High Throughput Screen</i> 1(2):57-72 (1998)	
	A197	MILLER <i>et al.</i> , "FLOG: A System to Select 'Quasi-Flexible' Ligands Complementary to a Receptor of Known Three-Dimensional Structure," <i>J. Comp. Aided Molec. Design</i> 8:153-174 (1994)	
	A198	MIRANKER and KARPLUS, "Functionality Maps of Binding Sites: A Multiple Copy Simultaneous Search Method," <i>Proteins: Structure, Function, and Genetics</i> 11:29-34 (1991)	
	A199	MITRA <i>et al.</i> , "Fluorescence Resonance Energy Transfer Between Blue-Emitting and Red-Shifted Excitation Derivatives of the Green Fluorescent Protein," <i>Gene</i> 173:13-17 (1996)	
	A200	MURRAY, "The Therapeutic Potential of PDE V <sub>A</sub> Inhibitors as, For Example, Vasodilators, Bronchodilators and Modulators of Gastrointestinal Motility, is Largely Based on the Effects of One Compound, Zaprinast, and a Clearer Picture Will be Obtained When Other Rationally Designed Inhibitors Become Available," <i>DN&amp;P</i> 6(3):150-156 (1993)	
✓	A201	NAVAZA, J., "AMoRe: An Automated Package for Molecular Replacement," <i>Acta Crystallogr. A</i> 50:157-163 (1994)	

Examiner Signature		Date Considered	6/15/06
--------------------	---	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/771,833
				Filing Date	02/03/2004
				First Named Inventor	Michael V. Milburn
				Group Art Unit	
				Examiner Name	
(use as many sheets as necessary)		Sheet 20 of 28		Attorney Docket Number 039363-1106	

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		
AK	A202	NEIDLE and JENKINS, "Molecular Modeling to Study DNA Intercalation by Anti-Tumor Drugs," <i>Methods Enz.</i> 203:433-458 (1991)		
	A203	NG, et al., "Engineering Protein-Lipid Interactions: Targeting of Histidine-Tagged Proteins to Metal-Chelating Lipid Monolayers," <i>Langmuir</i> 11:4048-4055 (1995)		
	A204	NICHOLLS et al., "Protein Folding and Association: Insights From the Interfacial and Thermodynamic Properties of Hydrocarbons," <i>Proteins</i> 11:281-296 (1991)		
	A205	NICHOLS et al., "Development of a Scintillation Proximity Assay for Peroxisome Proliferator-Activated Receptor $\gamma$ Ligand Binding Domain," <i>Anal. Biochem.</i> 257:112-119 (1998)		
	A206	O'SHANNESSY and WINZOR, "Interpretation of Deviations From Pseudo-First-Order Kinetic Behavior in the Characterization of Ligand Binding by Biosensor Technology," <i>Analytical Biochemistry</i> . 236:275-283 (1996)		
	A207	O'SHANNESSY, D., "Determination of Kinetic Rate and Equilibrium Binding Constants for Macromolecular Interactions: a Critique of the Surface Plasmon Resonance Literature," <i>Current Opinions in Biotechnology</i> . 5:65-71 (1994)		
	A208	OKADA et al., "Gene Therapy Against an Experimental Glioma Using Adeno-Associated Virus Vectors," <i>Gene Ther.</i> 3:957-964 (1996)		
↓	A209	OTWINOWSKI, Daresbury, United Kingdom, 80-86 (1991)		

Examiner Signature		Date Considered	6/15/06
--------------------	---	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/771,833
				Filing Date	02/03/2004
				First Named Inventor	Michael V. Milburn
				Group Art Unit	
				Examiner Name	
(use as many sheets as necessary)		Sheet 21 of 28		Attorney Docket Number 039363-1106	

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>6</sup>
AK	A210	OWICKIET et al., "Application of Fluorescence Polarization Assays in High-Throughput Screening," <i>Genetic Engineering News</i> 17:27 (1997)			
	A211	PAI, et al, "Structure for the Guanine-Nucleotide-Binding Domain of the Ha-ras Oncogene Product p21 in the Triphosphate Conformation," <i>Nature</i> 341:209-214 (1989)			
	A212	PARKER et al., "Development of High Throughput Screening Assays Using Fluorescence Polarization: Nuclear Receptor-Ligand-Binding and Kinase/phosphatase Assays," <i>J Biomol Screen</i> 5:77-88 (2000)			
	A213	PERCIVAL, et al., "Zinc Dependent Activation of cAMP-Specific Phosphodiesterase (PDE4A)," <i>Biochem. Biophys. Res. Commun.</i> 241:175-180 (1997)			
	A214	PERRIN D., "Nucleic Acids for Recognition and Catalysis: Landmarks, Limitations, and Looking to the Future," <i>Combinatorial Chemistry &amp; High Throughput Screening</i> 3:243-269 (2000)			
	A215	PFLUGRATH et al., "Crystal Structure Determination, Refinement and the Molecular Model of the $\alpha$ -Amylase Inhibitor Hoe-467A," <i>J. Mol. Biol.</i> 189:383-386 (1986)			
	A216	PLUNKETT and ELLMAN, "A Silicon-Based Linker For Traceless Solid-Phase Synthesis," <i>J. Org. Chem.</i> 60:6006-6007 (1995)			
↓	A217	POLTE and HANKS, "Interaction Between Focal Adhesion Kinase and Crk-Associated Tyrosine Kinase Substrate p130\$^{Cas}\$," <i>Proc Natl Acad Sci U.S.A.</i> 92:10678-10682 (1995)			

Examiner Signature		Date Considered	6/15/06
--------------------	---	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/771,833
				Filing Date	02/03/2004
				First Named Inventor	Michael V. Milburn
				Group Art Unit	
				Examiner Name	
(use as many sheets as necessary)				Attorney Docket Number	039363-1106
Sheet	22	of	28		

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
AK	A218	POUL et al., "Selection of Tumor-Specific Internalizing Human Antibodies From Phage Libraries," <i>Journal of Molecular Biology</i> 301:1149-1161 (2000)	
	A219	PRICE et al.; "Summary Report on the ISOBM TD-4 Workshop: Analysis of 56 Monoclonal Antibodies Against the MUC1 Mucin," <i>Tumor Biology</i> 19(Suppl 1):1-20 (1998)	
	A220	RIDLEY and HALL, "Signal Transduction Pathways Regulating Rho-Mediated Stress Fibre Formation: Requirement For a Tyrosine Kinase," <i>The EMBO Journal</i> 13(11):2600-2610 (1994)	
	A221	ROBERTS, et al., "Generation of an Antibody With Enhanced Affinity and Specificity For Its Antigen by Protein Engineering," <i>Nature</i> 328:731-734 (1987)	
	A222	RODRIGUEZ-PENA, et al., "Rapid Dephosphorylation of A Mr 80000 Protein, a Specific Substrate of Protein Kinase C Upon Removal of Phorbol Esters, Bombesin and Vasopressin," <i>Biochemical and Biophysical Research Communication</i> 140(1):379-385 (1986)	
	A223	ROSENFIELD, M., "Human Artificial Chromosomes Get Real," <i>Nat. Genet.</i> 15:333-335 (1997)	
	A224	ROTELLA, "Phosphodiesterase 5 Inhibitors: Current Status and Potential Applications," <i>Nature Reviews</i> 1:674-682 (2002)	
✓	A225	SAIKI, R., "Amplification of Genomic DNA," <i>PCR Protocols</i> 13-20 (1990)	

Examiner Signature		Date Considered	6/15/06
--------------------	---	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/771,833
				Filing Date	02/03/2004
				First Named Inventor	Michael V. Milburn
				Group Art Unit	
				Examiner Name	
(use as many sheets as necessary)				Attorney Docket Number	039363-1106
Sheet	23	of	28		

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>6</sup>
AK	A226	SAMBROOK <i>et al.</i> , "Introduction of Recombinant Vectors into Mammalian Cells," <i>Molecular Cloning: 2<sup>nd</sup> Ed.</i> , 16.30-16.37 (1989)			
	A227	SANCHEZ, <i>et al.</i> , "Cyclic-GMP-Binding, Cyclic-GMP-Specific Phosphodiesterase (PDE5) Gene Expression is Regulated During Rat Pulmonary Development," <i>Pediatric Research</i> 43:163-168 (1998)			
	A228	SASAKI <i>et al.</i> , "Cloning and Characterization of Cell Adhesion Kinase $\beta$ , a Novel Protein-Tyrosine Kinase of the Focal Adhesion Kinase Subfamily," <i>J Biol Chem.</i> 270:21206-21219 (1995)			
	A229	SCHALLER <i>et al.</i> , "Autonomous Expression of a Noncatalytic Domain of the Focal Adhesion-Associated Protein Tyrosine Kinase pp125 <sup>FAK</sup> ," <i>Mol. Cell. Biol.</i> 13(2):785-791 (1993)			
	A230	SCHALLER, <i>et al.</i> , "pp125\$(FAK)\$, a Structurally Distinctive Protein-Tyrosine Kinase Associated with Focal Adhesions," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 89:5192-5196 (1992)			
	A231	SCHLAEPFER <i>et al.</i> , "Signaling Through Focal Adhesion Kinase," <i>Prog in Biophys Mol Biol.</i> 71:435-478 (1999)			
	A232	SCHLESSINGER, J., "Signal Transduction by Allosteric Receptor Oligomerization," <i>Trends Biochem. Sci.</i> , 13:443-47 (1988)			
✓	A233	SCHNEIDER, <i>et al.</i> , "Functional Purification of a Bacterial ATP-Binding Cassette Transporter Protein (MalK) From the Cytoplasmic Fraction of an Overproducing Strain," <i>Protein Expr. Purif.</i> 6:10-14 (1995)			

Examiner Signature		Date Considered	6/15/06
--------------------	---	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<b>Complete If Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	10/771,833
				Filing Date	02/03/2004
				First Named Inventor	Michael V. Milburn
				Group Art Unit	
				Examiner Name	
(use as many sheets as necessary)				Attorney Docket Number	
Sheet	24	of	28	039363-1106	

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		
AK	A234	SCHREY, et al., "Bombesin and Glucocorticoids Stimulate Human Breast Cancer Cells to Produce Endothelin, a Paracrine Mitogen for Breast Stromal Cells," <i>Cancer Research</i> 52:1786-1790 (1992)		T <sup>6</sup>
	A235	SCHUHMAN, et al., "Immobilization of Enzymes on Langmuir-Blodgett Films Via a Membrane-Bound Receptor. Possible Applications for Amperometric Biosensors," <i>Adv. Mater.</i> 3:388-391 (1991)		
	A236	SCHUMMER, et al., "Inexpensive Handheld Device For the Construction of High-Density Nucleic Acid Arrays," <i>Biotechniques</i> 23:1087-1092 (1997)		
	A237	SCHWEIZER and HINGSGAUL, "Combinatorial Synthesis of Carbohydrates," <i>Curr Opin Chem Biol</i> 3(3):291-298 (1999)		
	A238	SEKHAR, et al., "Design and Synthesis of Xanthines and Cyclic GMP Analogues as Potent Inhibitors of PDE5," <i>Phosphodiesterase Inhibitors</i> 135-146 (1996)		
	A239	SELVIN, P., "Fluorescence Resonance Energy Transfer," <i>Meth. Enzymol.</i> 246:300-345 (1995)		
	A240	SHATTIL et al., "Tyrosine Phosphorylation of pp125 <sup>FAK</sup> in Platelets Requires Coordinated Signaling Through Integrin and Agonist Receptors," <i>J. Biol. Chem.</i> 269(20):14738-14745 (1994)		
↓	A241	SHEETS et al., "Efficient Construction of a Large Nonimmune Phage Antibody Library: the Production of High-Affinity Human Single-Chain Antibodies to Protein Antigens," (published erratum) <i>Proc Natl Acad Sci USA</i> 95:6157-6162 (1998)		

Examiner Signature		Date Considered	6/15/06
--------------------	---	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/771,833
				Filing Date	02/03/2004
				First Named Inventor	Michael V. Milburn
				Group Art Unit	
				Examiner Name	
(use as many sheets as necessary)				Attorney Docket Number	
Sheet	25	of	28	039363-1106	

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		
AK	A242	SHETH, et al., "Isolation and Regulation of the cGMP-Inhibited cAMP Phosphodiesterase in Human Erythroleukemia Cells," <i>Throm. Haemostasis</i> 77:155-162 (1997)		T <sup>6</sup>
	A243	SIEG, et al., "FAK Integrates Growth-Factor and Integrin Signals to Promote Cell Migration," <i>Nat Cell Biol.</i> 2:249-257 (2000)		
	A244	SIEGEL et al., "Mass Spectral Analysis of a Protein Complex Using Single-Chain Antibodies Selected on a Peptide Target: Applications to Functional Genomics," <i>Journal of Molecular Biology</i> 302:285-293 (2000)		
	A245	SIGAL, et al., "A Self-Assembled Monolayer for the Binding and Study of Histidine-Tagged Proteins by Surface Plasmon Resonance," <i>Anal. Chem.</i> 68:490-497 (1996)		
	A246	SMITH, et. al., "Necklace-Coded Polymer-Supported Combinatorial Synthesis of 2-Arylaminobenzimidazoles," <i>J. Comb. Chem.</i> 1:368-370 (1999)		
	A247	SOLINAS-TOLDO, et al., "Matrix-Based Comparative Genomic Hybridization: Biochips to Screen for Genomic Imbalances," <i>Genes, Chromosomes &amp; Cancer</i> 20:399-407 (1997)		
	A248	SRIVASTAVA, et al., "Effects of Magnesium on Cyclic GMP Hydrolysis by the Bovine Retinal Rod Cyclic GMP Phosphodiesterase," <i>Biochem. J.</i> 308:653-658 (1995)		
✓	A249	SUN, C., "Recent Advances in Liquid-Phase Combinatorial Chemistry," <i>Combinatorial Chemistry &amp; High Throughput Screening</i> 2:299-318 (1999)		

Examiner Signature		Date Considered	6/15/06
--------------------	---	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/771,833
				Filing Date	02/03/2004
				First Named Inventor	Michael V. Milburn
				Group Art Unit	
				Examiner Name	
(use as many sheets as necessary)				Attorney Docket Number	039363-1106
Sheet	26	of	28		

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			
AK	A250	TAHER <i>et al.</i> , "Phosphodiesterase Activity in Human Cavernous Tissue and the Effect of Various Selective Inhibitors," <i>J. Urol.</i> 149:285A (1993)			
	A251	TAYLOR <i>et al.</i> , "The Rapid Generation of Oligonucleotide-directed Mutations at High Frequency Using Phosphorothioate-Modified DNA," <i>Nucl. Acids Res.</i> 13:8764-8785 (1985)			
	A252	THOMAS, <i>et al.</i> , "Characterization of a Purified Bovine Lung cGMP-binding cGMP Phosphodiesterase," <i>J. Biol. Chem.</i> 265:14964-14970 (1990)			
	A253	THOMAS, <i>et al.</i> , "Substrate- and Kinase-directed Regulation of Phosphorylation of a cGMP-binding Phosphodiesterase by cGMP," <i>J. Biol. Chem.</i> 265:14971-14978 (1990)			
	A254	TURKO, <i>et al.</i> , "Identification of Key Amino Acids in a Conserved cGMP-binding Site of cGMP-binding Phosphodiesterase (PDE5)," <i>J. Biol. Chem.</i> 271:22240-22244 (1996)			
	A255	TURKO, <i>et al.</i> , "Potential Roles of Conserved Amino Acids in the Catalytic Domain of the cGMP-binding cGMP-specific Phosphodiesterase (PDE5)," <i>J. Biol. Chem.</i> 273:6460-6466 (1998)			
✓	A256	ULLRICH and SCHLESSINGER, "Signal Transduction by Receptors With Tyrosine Kinase Activity," <i>Cell</i> 61:203-212 (1990)			
✓	A257	UNDENFRIEND <i>et al.</i> , "Scintillation Proximity Assay: A Sensitive and Continuous Isotopic Method for Monitoring Ligand/Receptor and Antigen/Antibody Interactions," <i>Anal. Biochem.</i> 161:494-500 (1987)			

Examiner Signature		Date Considered	6/15/06
--------------------	---	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/771,833
				Filing Date	02/03/2004
				First Named Inventor	Michael V. Milburn
				Group Art Unit	
				Examiner Name	
(use as many sheets as necessary)					
Sheet	27	of	28	Attorney Docket Number	039363-1106

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>6</sup>
<i>AK</i>	A258	VAN REGENMORTEL, "Use of Biosensors to Characterize Recombinant Proteins," <i>Developments in Biological Standardization</i> 83:143-151 (1994)			
	A259	VELY et al., "BIAcore <sup>®</sup> Analysis to Test Phosphopeptide-SH2 Domain Interactions," <i>Methods in Molecular Biology</i> 121:313-321 (2000)			
	A260	WEBER, G., "Energetics of Ligand Binding to Proteins," <i>Adv. Protein Chem.</i> 29:1-83 (1975)			
	A261	WEBER, P., "Physical Principles of Protein Crystallization," <i>Adv. Protein Chem.</i> 41:1-36 (1991)			
	A262	WESSJOHANN, "Synthesis of Natural-Product-Based Compound Libraries," <i>Curr Opin Chem Biol</i> 4(3):303-309 (2000)			
	A263	WHARAM et al., "Specific Detection of DNA and RNA Targets Using a Novel Isothermal Nucleic Acid Amplification Assay Based on the Formation of a Three-Way Junction Structure," <i>Nucleic Acids Res.</i> 29(11):E54-E54 (2001)			
	A264	WILK-BLASZCZAK et al., "Bradykinin Modulates Potassium and Calcium Currents in Neuroblastoma Hybrid Cells Via Different Pertussis Toxin-Insensitive Pathways," <i>Neuron</i> 12:109-116 (1994)			
<i>✓</i>	A265	WILLIAMS, et al., "Dissection of Extracellular Human Interferon $\gamma$ Receptor $\alpha$ -Chain Into Two Immunoglobulin-Like Domains. Production in an <i>Escherichia coli</i> Thioredoxin Gene Fusion Expression System and Recognition by Neutralizing Antibodies," <i>Biochemistry</i> 34:1787-1797 (1995)			

Examiner Signature	<i>Michael V. Milburn</i>	Date Considered	6/15/06
--------------------	---------------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/771,833
				Filing Date	02/03/2004
				First Named Inventor	Michael V. Milburn
				Group Art Unit	
				Examiner Name	
(use as many sheets as necessary)				Attorney Docket Number	039363-1106
Sheet	28	of	28		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		
AK	A266	WOON, et al., "Construction and Characterization of a 10-Fold Genome Equivalent Rat P1-Derived Artificial Chromosome Library," <i>Genomics</i> 50:306-316 (1998)		T <sup>6</sup>
	A267	WYATT et al., "ANF Elicits Phosphorylation of the cGMP Phosphodiesterase in Vascular Smooth Muscle Cells," <i>Am. J. Physiol.</i> 274:H448-H455 (1998)		
	A268	XIONG and PARSONS, "Induction of Apoptosis After Expression of PYK2, a Tyrosine Kinase Structurally Related to Focal Adhesion Kinase," <i>J Cell Biol.</i> 139:529-539 (1997)		
	A269	YAMAZAKI et al., "Enzyme Regulation and GTP Binding Protein: An Algorithm of Control That Includes Physical Displacement of an Inhibitory Protein," <i>Adv. Cyclic Nucleotide Protein Phosphorylation Res.</i> 16:381-392 (1984)		
↓	A270	YANAKA, et al., "Expression, Structure and Chromosomal Localization of the Human cGMP-binding cGMP-specific Phosphodiesterase PDE5A Gene," <i>J. Biochem.</i> 255:391-399 (1998)		

Examiner Signature		Date Considered	6/15/06
--------------------	---	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.